Your browser doesn't support javascript.
Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies.
Cotugno, Nicola; Ruggiero, Alessandra; Bonfante, Francesco; Petrara, Maria Raffaella; Zicari, Sonia; Pascucci, Giuseppe Rubens; Zangari, Paola; De Ioris, Maria Antonietta; Santilli, Veronica; Manno, E C; Amodio, Donato; Bortolami, Alessio; Pagliari, Matteo; Concato, Carlo; Linardos, Giulia; Campana, Andrea; Donà, Daniele; Giaquinto, Carlo; Brodin, Petter; Rossi, Paolo; De Rossi, Anita; Palma, Paolo.
  • Cotugno N; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata," 00185 Rome, Italy.
  • Ruggiero A; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Bonfante F; Laboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, 35020 Legnaro, Italy.
  • Petrara MR; Section of Oncology and Immunology, Department of Surgery, Oncology, and Gastroenterology, Unit of Viral Oncology and AIDS Reference Center, University of Padova, 35128 Padova, Italy.
  • Zicari S; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Pascucci GR; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Zangari P; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • De Ioris MA; Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Santilli V; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Manno EC; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Amodio D; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata," 00185 Rome, Italy.
  • Bortolami A; Laboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, 35020 Legnaro, Italy.
  • Pagliari M; Laboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, 35020 Legnaro, Italy.
  • Concato C; Department of Laboratories, Division of Virology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Linardos G; Department of Laboratories, Division of Virology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Campana A; Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Donà D; Department of Mother and Child Health, University of Padova, 35128 Padova, Italy.
  • Giaquinto C; Department of Mother and Child Health, University of Padova, 35128 Padova, Italy.
  • Brodin P; Pediatric Rheumatology, Karolinska University Hospital, 17177 Stockholm, Sweden.
  • Rossi P; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata," 00185 Rome, Italy.
  • De Rossi A; Section of Oncology and Immunology, Department of Surgery, Oncology, and Gastroenterology, Unit of Viral Oncology and AIDS Reference Center, University of Padova, 35128 Padova, Italy; Istituto Oncologico Veneto (IOV)-IRCCS, 35128 Padova, Italy.
  • Palma P; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata," 00185 Rome, Italy. Electronic address: paolo.palma@opbg.n
Cell Rep ; 34(11): 108852, 2021 03 16.
Article in English | MEDLINE | ID: covidwho-1135278
Semantic information from SemMedBD (by NLM)
1. 2019 novel coronavirus PROCESS_OF Child
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Child
2. Anti-Antibodies PART_OF 2019 novel coronavirus
Subject
Anti-Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
3. Child LOCATION_OF Anti-Antibodies
Subject
Child
Predicate
LOCATION_OF
Object
Anti-Antibodies
4. Anti-Antibodies AFFECTS B-Lymphocytes
Subject
Anti-Antibodies
Predicate
AFFECTS
Object
B-Lymphocytes
5. Anti-Antibodies AFFECTS T-Lymphocyte
Subject
Anti-Antibodies
Predicate
AFFECTS
Object
T-Lymphocyte
6. Plasma LOCATION_OF Proteome
Subject
Plasma
Predicate
LOCATION_OF
Object
Proteome
7. 2019 novel coronavirus PROCESS_OF Child
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Child
8. Anti-Antibodies PART_OF 2019 novel coronavirus
Subject
Anti-Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
9. Child LOCATION_OF Anti-Antibodies
Subject
Child
Predicate
LOCATION_OF
Object
Anti-Antibodies
10. Anti-Antibodies AFFECTS B-Lymphocytes
Subject
Anti-Antibodies
Predicate
AFFECTS
Object
B-Lymphocytes
11. Anti-Antibodies AFFECTS T-Lymphocyte
Subject
Anti-Antibodies
Predicate
AFFECTS
Object
T-Lymphocyte
12. Plasma LOCATION_OF Proteome
Subject
Plasma
Predicate
LOCATION_OF
Object
Proteome
ABSTRACT
As the global COVID-19 pandemic progresses, it is paramount to gain knowledge on adaptive immunity to SARS-CoV-2 in children to define immune correlates of protection upon immunization or infection. We analyzed anti-SARS-CoV-2 antibodies and their neutralizing activity (PRNT) in 66 COVID-19-infected children at 7 (±2) days after symptom onset. Individuals with specific humoral responses presented faster virus clearance and lower viral load associated with a reduced in vitro infectivity. We demonstrated that the frequencies of SARS-CoV-2-specific CD4+CD40L+ T cells and Spike-specific B cells were associated with the anti-SARS-CoV-2 antibodies and the magnitude of neutralizing activity. The plasma proteome confirmed the association between cellular and humoral SARS-CoV-2 immunity, and PRNT+ patients show higher viral signal transduction molecules (SLAMF1, CD244, CLEC4G). This work sheds lights on cellular and humoral anti-SARS-CoV-2 responses in children, which may drive future vaccination trial endpoints and quarantine measures policies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines Limits: Child / Humans Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.108852

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines Limits: Child / Humans Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.108852